News | Heart Valve Technology | August 31, 2017

World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy

Gate tricuspid atrioventricular valved stent delivered to transplanted-heart patient to correct torrential tricuspid regurgitation

World's First Successful 52-mm Transcatheter Tricuspid Valve Implantation Completed in Italy

August 31, 2017 — NaviGate Cardiac Structures Inc. (NCSI) announced that its Gate catheter-guided tricuspid atrioventricular valved stent (AVS) was implanted through the jugular vein six weeks ago into a patient’s transplanted heart that was failing due to severe tricuspid valve insufficiency.  The successful implantation of the Gate AVS at the Policlinico of the University of Padua, Italy, represents the first European patient treated with the NCSI tricuspid replacement heart valve. Three hours after the intervention the patient was awake and showing improved renal function. Now, approximately two months post-procedure, the patient continues to demonstrate clinical improvement and excellent valvular function. This brings the total number of NCSI Gate tricuspid implants without 30-day mortality to three.

The patient, a 67-year-old male with a long history of cardiac conditions, received a heart transplant in 1990 for post-ischemic dilated cardiomyopathy and had a host of comorbidities [hypertension, osteoporosis with vertebral fracture, radical prostate surgery due to cancer (2006), and upper and middle right lobectomy for bullous dysplasia (2009)]. Since the beginning of 2017, the patient has had five hospitalizations for heart failure due to severe regurgitation of the tricuspid valve of his transplanted heart. When the patient was released home five days after the procedure, the Gate showed a transvalvular gradient of 2 mmHg with a trivial perivalvular leak. Also notable was that at discharge the patient’s renal function had improved significantly and a dramatic reduction in diuretics was prescribed. 

NCSI President and CEO Rodolfo Quijano, M.D., Ph.D., said it was the first implantation of a size-52 mm Gate AVS.

NCSI differentiates the Gate from all other valves presently manufactured for atrioventricular heart valve replacement by its delivery design in the form of a diffuser or truncated cone. This design for all annulus-capturing sizes exhibits a low height profile that can be more easily threaded through the vasculature to reach the atrioventricular valves, allowing it to reside without protruding into either of the adjacent chambers (atrium or ventricle) of dilated mitral or tricuspid valves, as protrusion is known to cause certain complications. 

Tricuspid regurgitation (TR) has lately received intensive attention after being ignored for decades as the aortic and mitral valves have been the focus of efforts in new transcatheter technology for repair or replacement. Moderate-to-severe TR is a burgeoning health problem both in the developed and underdeveloped world, and estimates in the United States alone are approaching the 2 million patient mark yearly. When at the severe stage, patients are at prohibitive risk for standard cardiac surgery. 

NCSI questioned if the atrioventricular Gate valve would be suitable for a transplanted heart and consulted with its scientific advisory board (SAB), a group that comprises, among others, Rebecca Hahn, M.D., from Columbia University Medical Center, N.Y., an expert cardiologist-echocardiographer in atrioventricular valves; and Azeem Latib, MB BCh, FCP, a well-known interventional cardiologist with extensive expertise in treatment of tricuspid valve disease from San Rafaelle Medical Center in Milan, Italy.

The NCSI SAB, acting as an ad hoc patient selection committee, examined the case and determined that the Gate device would be suitable for the transplanted heart. The patient had become symptomatic for right heart failure and was considered at prohibitive risk for standard cardiac surgery and opted to make a compassionate plea to Drs. Andrea Colli and Gino Gerosa, his physician surgeons, for the NCSI valved stent under development. The Italian Ministry of Health allowed the implant as a last resort for the patient. Prof. Giusseppe Tarantini, chief of interventional cardiology, and Colli proceeded with the implantation. It was ascertained that the measured diameter of the dilated annulus of the incompetent valve was so large that it would require a 52mm Gate, the largest tricuspid valved stent, in order to correct the torrential TR. After receiving the valve, the patient became stable and three hours after was awake and showing improved renal function.

Tarantini found the Gate device to be very “user-friendly,” adding: “I like this valve, it is easy to use and took less than 10 minutes to place once we entered the right atrium. This will be helpful to many patients with advanced tricuspid insufficiency.”

Tarantini will be leading the transjugular clinical implants in Padua while Gerosa and Colli will lead the transatrial surgical implants as the clinical trials commence.

NCSI’s technology is not approved for investigational use in the United States.

Watch the VIDEO "Transcatheter Tricuspid Valve Repair and Replacement Technologies," an interview with Rebecca Hahn at ASE 2017.

Watch the VIDEO "Mitral and Tricuspid Valve Repair Technologies," an interview with Azeem Latib at ACC.17.

For more information: www.navigatecsi.com

Related Content

CorInnova Awarded 2017 InnoSTARS Prize for EpicHeart Soft Robotic Heart Assist Device
News | Artificial Heart| December 11, 2017
CorInnova Inc. recently announced it was awarded second prize in the “2017 InnoSTARS” life science competition for its...
Edwards Acquires Harpoon Medical
News | Heart Valve Technology| December 07, 2017
December 7, 2017 — Edwards Lifesciences Corp.
Robocath Receives $1.5 Million in Capital for Advancement of R-One Robotic System
News | Robotic Systems| December 06, 2017
December 6, 2017 — French company Robocath, which designs and develops...
New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

New data on the Corvia intra-atrial shunt to treat diastolic heart failure were presented at the recent 2017 American Heart Association (AHA) Scientific Sessions. It was the most popular story in November.

Feature | December 06, 2017 | Dave Fornell
Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardiology (DAIC) magaz
New Tool Predicts Risk of Heart Attack in Older Surgery Patients
News | Cardiac Diagnostics| December 05, 2017
A tool designed to more accurately predict the risk of heart attack in older patients undergoing non-cardiac surgery...
Toshiba Medical Rolls Out Interactive Learning Tools for Ultrasound and Vascular Training
News | Ultrasound Imaging| December 04, 2017
Toshiba Medical, a Canon Group company, introduced new educational tools and interactive learning resources to help...
Philips Azurion Platform Improves Clinical Workflow and Staff Experience Benefits
News | Angiography| December 04, 2017
Philips recently announced the results of a comprehensive, independent, two-year study demonstrating the clinical...
Studies find 15 percent of all heart attack and stroke patients and 9 percent of CABG patients were uninsured before passage of the Affordable Care Act. AHA 2017, #aha2017
News | November 25, 2017
November 25, 2017 — The majority of patients without health insurance who were hospitalized for heart attack, stroke
The Corvia intra-atrial shunt to treat diastolic heart failure.

The Corvia intra-atrial shunt to treat diastolic heart failure.

Feature | Heart Failure| November 25, 2017
November 25, 2017 – Results presented at the 2017 American Heart Association (AHA) Scientific Sessions and published
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. 

Feature | Cath Lab| November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Overlay Init